Aignostics
PrivateLast Round
Series B
Oct 29, 2024
Total Funding Raised
$55.43M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Aignostics operates in Healthcare & Life Sciences and is based in Berlin. Its latest recorded funding round was a Series B round in October 2024.
Aignostics is a healthtech company that provides an artificial intelligence-driven image analysis platform to enhance precision medicine by providing explainable diagnostic insights for cancer and complex disease diagnosis and treatment.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Clinical Trials, Medical Imaging
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aignostics Comparables
Compare Aignostics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nucleai | 87% | |
| AIRA Matrix | 83% | |
| Tempus | 83% |
For institutional investors. Book with your work email.
Aignostics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 29, 2024 | ||||
| Grant | Mar 6, 2023 | ||||
| Series A | Sep 15, 2022 | ||||
| Seed | Aug 28, 2020 | ||||
| Accelerator | Jan 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Aignostics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| State of Berlin | Series B, Series A, Seed |
| IBB Ventures | Series B, Series A, Seed |
| Athos KG | Series B |
| European Regional Development Fund | Grant |
| Ascenion | Series B, Series A |
| Boehringer Ingelheim Venture Fund | Series B, Series A, Seed |
| Wellington Partners | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors grew 108% MoM, reaching 12.5K.
- Jun 5, 2026
Company is a spin-off from the Charité university hospital.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesOct 16, 2026
Aignostics launches HETA Clinical, a pan-cancer AI product range that accelerates pathology workflows and reduces failed molecular tests, in Germany and New York on Oct 16th '26.
- integrates_withSep 12, 2026
Aignostics integrates its PathoSearch application into Techcyte's Fusion AP, enabling pathologists to search for morphologically similar cases from within the slide viewer using the image rather than a written description, on Sep 12th '26 in Germany and Utah.
- launchesSep 12, 2026
Aignostics launches PathoSearch in early access on Sep 12th '26 in Germany and New York, offering image-based search that retrieves morphologically similar, diagnosed pathology cases from a multi-center reference database.
For institutional investors. Book with your work email.
Aignostics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Aignostics's valuation, stock price, and market status.
Is Aignostics a public or private company?
Aignostics is a private company.
What is the current stock price of Aignostics?
Aignostics is a private company, so its shares have no public market price. Caplight tracks Aignostics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Aignostics worth (valuation)?
Valuation information for Aignostics is not publicly available.
Can I buy Aignostics stock?
Aignostics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Aignostics's last funding round?
Aignostics's most recent funding round was Series B on October 29, 2024.
Who are the main investors in Aignostics?
Key investors in Aignostics include Athos KG, Boehringer Ingelheim Venture Fund, Wellington Partners.
Will Aignostics IPO soon?
No public IPO plans have been announced for Aignostics.
How can I track Aignostics secondary market activity?
Caplight tracks bids, offers, and trades in Aignostics's shares on secondary markets.